novartis novartis

573 posts   37,088 followers   62 followings

Novartis  Our purpose is to reimagine medicine to improve and extend people’s lives. See our Community Guidelines & more:

Despite the few external markers of broken capillaries and bruising, immune thrombocytopenia (ITP) is mostly a disease you don't see. Those with the disorder usually look like there is nothing wrong with them. But, for many patients, the hardest part of ITP are the limitations on what they can do and how tired and run down they get because of the severe fatigue.

When it comes to helping the whole patient dealing with immune thrombocytopenia (ITP), are doctors not listening or are patients not talking? New data from the I-WISh survey reveals a sizable disconnect in terms of the seriousness and personal impact fatigue has on patients.

When the shopkeeper measures blood pressure: The Novartis Foundation and partners have shown that making healthcare more accessible by bringing it closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease. The control rate of people with hypertension who were enrolled in the ComHIP program in Ghana for 12 months climbed from 36% to 72%. The Ghanaian government is now integrating the model into national policy and plans to scale-up to additional regions. We believe this simple form of community-based care could save millions of lives in other countries and for other NCDs @ministryofhealthghana @LSHTM @FHI360 📷 @globalhealthphotography

“Including the patient perspective in all our activities will ensure that patients receive the right product, for the right reasons, at the right time.” #HowWeSeeIt #WorkingWithPatients
.
.
Shannon Klinger
Group General Counsel of Novartis

For decades, we have been pioneering new ways to improve access to medicines and healthcare.
.
But we need to do more to make today’s medical innovations available to more people.
.
We are embarking on a journey to change the way we operate through our Access Principles. #AccessinAction

“Be bold.” Dr. Botond Roska, director of the Institute of Molecular and Clinical Ophthalmology explains why healthcare researchers should dare to address the impossible.

For 150 years, pathologists have been looking through microscopes at tissue samples mounted on slides to diagnose cancer to determine whether a patient has cancer or not. The job of a pathologist can be daunting--a single slide could contain hundreds of thousands of cells and only a handful might be cancer.
.
Novartis pathologists think artificial intelligence (#AI) might have an additional role to play in pathology—that the slides could contain information that helps explain why some patients respond to therapy when other seemingly similar patients do not.
.
By teaming up with @unibasel, @unispitalbasel and AI startup, PathAI, we’re training an AI system to learn to see the same patterns pathologists see and then building on that to determine if the system can detect hidden but informative patterns too subtle or complex for pathologists to recognize. In turn, the AI platform shows us what the machine sees—regions of the cells determined to be cancer glow bright red in a field of green surrounding tissue.
.
The effort is part of a larger effort at Novartis to leverage data and digital technologies in ways that could help drug developers get the right drugs to the right patients faster.

“I used to constantly think about how I could get closer to the patient in this industry. The Novartis Commitment to Patient and Caregivers made it really clear and simple, it can guide me in my decision-making on a daily basis. For me, it absolutely helps clarify my purpose for coming to work every day.” #HowWeSeeIt #WorkingWithPatients
.
.
Laura McKeaveney
Global Head of Patient Advocacy,
Novartis

#FBF with our incredible ambassadors. When we work together, we have the ability to enact change. Join us,@mycancerchic and the rest of the #KissThis4MBC team to raise awareness and research funds for #MBC.

A computer knows what a normal cell looks like,” explains scientist Mark Bray as he describes how #machinelearning can help us speed up drug discovery. We give the computer a bunch of examples of what these normal untreated cells look like, and from there it can learn what the signature, or fingerprint, of an untreated cell is and define all other treatments against that one. All the machine needs to do is basically look for something that’s different than the normal cell. And a machine can do that much faster, and can look for much more subtle features than the human 👁 can possibly see.

We are made up of thousands of researchers, 250 data scientists, and we’ve collected 15 petabytes of data. Our Chief Digital Officer, Bertrand Bodson, answers some questions on how we plan to use these incredible resources:
.
How is Novartis getting into data science?
.
We have a ton of data. In terms of clinical trial data, over the past two decades we’ve collected 2 million patient-years of data. Very few pharmaceutical companies have that. Some of the largest, most respected and most innovative digital technologies companies are knocking at our door asking for access to that dataset.

We’re seeing a confluence of digital technology and data science with chemistry, biology and clinical research.

How can the data be used?

Now, instead of only looking at one set of data, we’re looking at the data from decades of clinical trials and asking, what if we were to mine all of it together?

We hope to make connections that would be impossible with a smaller dataset. For instance, could one of our drugs help treat a disease we didn’t suspect? Could the data point to better ways to stratify patients so that we can be better at getting our medicines to the patients who will benefit most?

In and outside of the lab, we’re proud to be a 2018 Science Top Employer reimagining medicine.

Most Popular Instagram Hashtags